Eli Lilly and Co (LLY) Osake Kurssi
Eli Lilly and Co Kurssi
Liikevaihto on kasvanut 7,8 % vuodessa viimeisten 19 vuoden aikana 65,18 Mrd. USD:een. Osakekohtainen tulos on kasvanut 12,5 % vuodessa viimeisten 19 vuoden aikana. Eli Lilly and Con nettomarginaali on nyt 31,7 %, noussut 19,7 %:sta muutama vuosi sitten. Eli Lilly and Con osinkotuotto on tällä hetkellä noin 0,43 %. Jakosuhde on noin 26 % tuloksesta. Osinko on kasvanut 7,2 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 1 360,00 USD, eli ali nykyhintaa 3,5 %. 37 analyytikosta 32 suosittaa ostoa — kokonaiskonsensus on Osta.
Eli Lilly and Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Eli Lilly and Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Eli Lilly and Co -osakkeesta
The business model of Eli Lilly and Co. revolves around research, development, and commercialization of pharmaceutical products. As one of the leading global pharmaceutical companies, Eli Lilly focuses on discovering innovative medicines to treat diseases and improve patients' lives. Through extensive research and collaboration, the company develops a wide range of therapeutic solutions across various areas such as diabetes, oncology, immunology, and neuroscience. By consistently investing in R&D, Eli Lilly strives to bring new treatments to market, ensuring quality healthcare and offering value to patients, healthcare professionals, and stakeholders worldwide.
Eli Lilly and Co is primarily active in the pharmaceutical industry.
The main competitors of Eli Lilly and Co in the market are pharmaceutical companies such as Pfizer, Johnson & Johnson, Merck & Co., Novartis, and Sanofi.
Eli Lilly and Co, founded in 1876, is a leading global pharmaceutical company headquartered in Indianapolis. With a rich history spanning over 140 years, Eli Lilly and Co has consistently focused on discovering, developing, and marketing innovative pharmaceutical products that improve people's lives. The company is committed to addressing crucial medical needs through its diverse portfolio of medicines and has made notable contributions in areas like diabetes, cancer, neuroscience, and immunology. Over the years, Eli Lilly and Co has established a strong reputation for its scientific expertise, ethical business practices, and dedication to ensuring patient safety and well-being.
Eli Lilly and Co, a renowned pharmaceutical company, has achieved significant milestones over the years. It pioneered the first commercially available insulin, revolutionizing diabetes treatment. The company also developed Prozac, a widely used antidepressant, contributing to mental health care. Eli Lilly collaboratively discovered Erbitux, an anti-cancer drug, which has transformed the treatment of colorectal cancer. Furthermore, the company introduced Humalog, a fast-acting insulin analog, enhancing diabetes management. Eli Lilly and Co has consistently demonstrated its commitment to innovation and improving patients' lives with its groundbreaking pharmaceutical developments.
Eli Lilly and Co is primarily present in various countries and regions worldwide. The company's global presence extends to markets such as the United States, Europe, Asia, and Latin America. With a strong foothold in the pharmaceutical industry, Eli Lilly and Co operates across multiple continents, including North America, where it is headquartered in Indianapolis, Indiana. Additionally, the company's international operations expand into key pharmaceutical markets like Canada, Germany, the UK, Japan, China, and Brazil. Ensuring a widespread reach, Eli Lilly and Co's presence remains significant on a global scale, contributing to its reputation as a leading pharmaceutical player.
Eli Lilly and Co is a renowned pharmaceutical company with a strong set of values and corporate philosophy. They prioritize patient well-being and improving lives through their innovative healthcare solutions. Their commitment to integrity and high ethical standards reflects in their extensive research and development efforts. Eli Lilly and Co aims to provide quality products that address unmet medical needs while fostering a culture of inclusivity and diversity within their organization. By consistently adhering to their core values, the company has become a global leader and a trustworthy partner in the pharmaceutical industry.
Analyytikot asettavat tällä hetkellä Eli Lilly and Co-osakkeelle keskimääräisen tavoitehinnan 1 341,63 USD (mediaani: 1 360,00 USD), mikä merkitsee −3,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 37 analyytikkoarvioon.
37 analyytikkoa arvioi tällä hetkellä Eli Lilly and Co-osaketta: 32 suosittaa ostoa, 4 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Eli Lilly and Co-yhtiöltä 88,76 Mrd. USD liikevaihtoa ja 34,10 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Eli Lilly and Co-osake noteerataan hintaan 1 259,18 EUR (1 409,38 USD).
Eli Lilly and Co-osake (LLY) on listattuna 10 pörssissä, muun muassa: NYSE (LLY), London (0Q1G.L), SIX (Zürich) (LLY.SW), XETRA (LLY.DE), Frankfurt (LLY.F), München (LLY.MU), Düsseldorf (LLY.DU), Hamburg (LLY.HM).
Eli Lilly and Co is a globally active company in the healthcare sector. Its business model focuses on developing, manufacturing, and marketing innovative drugs and healthcare products to have positive impacts on people's lives. The company operates in three main business areas: human pharmaceuticals, animal health, and biotechnology. In the field of human pharmaceuticals, the company offers a wide range of drugs for the treatment of diseases such as diabetes, cancer, arthritis, neurology, and more. Some of its well-known products include Humalog, Trulicity, Taltz, Jardiance, Forteo, and Alimta. Eli Lilly and Co is also a major player in the animal health sector, providing veterinarians and pet owners with a wide range of drugs and services. This includes specialized products for the treatment of dogs, cats, horses, cattle, pigs, and poultry. Through its biotechnology business areas, Eli Lilly and Co is also dedicated to the development of innovative therapies and technologies. It focuses on autoimmune diseases, pain management, cancer research, and affordable healthcare in emerging markets. To ensure the success of its business model, Eli Lilly and Co invests billions annually in research and development of new drugs and healthcare solutions. A significant portion of these funds goes into clinical trials to ensure the safety and efficacy of the drugs. Eli Lilly and Co intends to further expand its business by focusing on partnerships, mergers, and acquisitions to expand its portfolio and capabilities. In this context, the company has recently undertaken a number of acquisitions and partnerships, including Loxo Oncology, ImClone Systems, Sitryx, Armo BioSciences, and AC Immune. Eli Lilly and Co generates revenue worldwide by selling its products directly to retailers, collaborating closely with doctors and other medical professionals, and selling its products to wholesalers and pharmacies. The company also operates its own facilities to provide medical services and products to people and pets. In summary, Eli Lilly and Co is a leading company in the healthcare sector that aims to provide innovative and life-changing solutions for patients and pets worldwide. Through research, development, and strategic partnerships, the company has built a wide range of products and extensive expertise to effectively serve its customers and expand its presence in the global healthcare market.
odotettu liikevaihto Eli Lilly and Co on 88,76 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Eli Lilly and Co on 30,62 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Eli Lilly and Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 41,33. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Eli Lilly and Co-osakkeen arvostusta.
Eli Lilly and Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 14,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Eli Lilly and Co-osakkeen arvostuskennuslukuna.
Eli Lilly and Co:n Eulpool-laatuscore on 9/10.
Eli Lilly and Co:n ISIN on US5324571083. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Eli Lilly and Co:n WKN on 858560. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Eli Lilly and Co:n ticker on LLY. Tämä pörssinoteeraus käytetään Eli Lilly and Co-osakkeiden kauppaan pörssissä.
Eli Lilly and Co osake
Eli Lilly and Co vertaisryhmä
Eli Lilly and Co Ticker
Eli Lilly and Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Eli Lilly and Co:sta
Meidän osakeanalyysimme Eli Lilly and Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Eli Lilly and Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: